Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Chinese University of Hong Kong |
---|---|
Information provided by: | Chinese University of Hong Kong |
ClinicalTrials.gov Identifier: | NCT00125307 |
The investigators study the efficacy and safety of tacrolimus in the treatment of membranous nephritis secondary to systemic lupus erythematosus.
Condition | Intervention | Phase |
---|---|---|
Lupus Nephritis Lupus Erythematosus, Systemic |
Drug: tacrolimus |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis |
Estimated Enrollment: | 20 |
Study Start Date: | January 2004 |
Study Completion Date: | February 2008 |
Primary Completion Date: | October 2007 (Final data collection date for primary outcome measure) |
Glomerulonephritis is one of the major disease manifestations of systemic lupus erythematosus (SLE). The treatment of membranous (type V) lupus nephritis, a subset that carries a high morbidity, remains unsatisfactory. Recent studies suggest that immunosuppressive therapy targeted against the calcineurin pathway of T-helper cells, for example, tacrolimus, may be effective in the treatment of primary membranous nephropathy. The investigators plan to conduct an open-label single-arm study of the efficacy and safety of tacrolimus in the treatment of membranous nephropathy secondary to SLE. Twenty patients with biopsy-proven membranous nephropathy secondary to SLE will be recruited. They will be treated with oral prednisolone and tacrolimus for 6 months, followed by 6 months of maintenance steroids alone. Proteinuria, renal function, clinical and serologic lupus activity will be monitored. Complete remission is defined as 24-hour urinary protein excretion to less than 0.5 gm/day. This study will explore the potential role of tacrolimus in the treatment of membranous lupus nephritis, which is usually resistant to conventional therapy.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
China | |
Department of Medicine & Therapeutics, Prince of Wales Hospital | |
Hong Kong, China |
Principal Investigator: | Cheuk-Chun Szeto, MD | Chinese University of Hong Kong |
Study ID Numbers: | CRE-2004.229-T, CRE-2004.229-T |
Study First Received: | July 29, 2005 |
Last Updated: | May 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00125307 |
Health Authority: | Hong Kong: Joint CUHK-NTEC Clinical Research Ethics Committee; Hong Kong: Department of Health |
SLE glomerulonephritis immunosuppressive therapy type V (membranous) lupus nephritis |
Glomerulonephritis Autoimmune Diseases Urologic Diseases Lupus Erythematosus, Systemic Lupus Nephritis |
Nephritis Connective Tissue Diseases Tacrolimus Kidney Diseases |
Immunologic Factors Immune System Diseases Physiological Effects of Drugs Immunosuppressive Agents Pharmacologic Actions |